Kinetics and mechanisms of activation of α-amino acid ester prodrugs of camptothecins

Journal of Medicinal Chemistry

Volumn 49, Issue 14, 2006, Pages 4344-4355

  Song, Lin ^a   Bevins, Robert ^b   Anderson, Bradley D ^a  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO ACID; CAMPTOTHECIN DERIVATIVE; DB 67; LIPOSOME; PRODRUG; SILATECAN 7 TERT BUTYLDIMETHYLSILYL 10 HYDROXYCAMPTOTHECIN; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CELL DEATH; DNA REPLICATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STABILITY; ENZYME MECHANISM; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; HYDROLYSIS; LIPOPHILICITY; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; QUANTITATIVE ANALYSIS; STRUCTURE ACTIVITY RELATION;

AMINO ACIDS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ESTERS; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; KINETICS; LACTAMS; LACTONES; MAGNETIC RESONANCE SPECTROSCOPY; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745855129     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060016l     Document Type: Article

References (37)

1. Hertzberg, R. P.; Caranfa, M. J.; Hecht, S. M. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 1989, 28, 4629-4638.
2. Hsiang, Y. H.; Lihou, M. G.; Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989, 49, 5077-5082.
3. Jaxel, C.; Kohn, K. W.; Wani, M. C.; Wall, M. E.; Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 1989, 49, 1465-1469.
4. Fassberg, J.; Stella, V. J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 1992, 81, 676-684.
5. Mi, Z.; Burke, T. G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 1994, 33, 10325-10336.
6. Bom, D.; Curran, D. P.; Kruszewski, S.; Zimmer, S. G.; Thompson Strode, J.; Kohlhagen, G.; Du, W.; Chavan, A. J.; Fraley, K. A.; Bingcang, A. L.; Latus, L. J.; Pommier, Y.; Burke, T. G. The novel silatecan 7-tert-butyldimethylsilyl- 10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J. Med. Chem. 2000, 43, 3970-3980.
7. Bom, D.; Curran, D. P.; Chavan, A. J.; Kruszewski, S.; Zimmer, S. G.; Fraley, K. A.; Burke, T. G. Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. J. Med. Chem. 1999, 42, 3018-3022.
8. Bom, D.; Curran, D. P.; Zhang, J.; Zimmer, S. G.; Bevins, R.; Kruszewski, S.; Howe, J. N.; Bingcang, A.; Latus, L. J.; Burke, T, G. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J. Control. Rel. 2001, 74, 325-333.
9. Pollack, I. F.; Erff, M.; Bom, D.; Burke, T. G.; Strode, J. T.; Curran, D. P. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res. 1999, 59, 4898-4905.
10. Liu, X.; Lynn, B. C.; Zhang, J.; Song, L.; Bom, D.; Du, W.; Curran, D. P.; Burke, T. G. A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs. J. Am. Chem. Soc. 2002, 124, 7650-7651.
11. Colbern, G. T.; Dykes, D. J.; Engbers, C.; Musterer, R.; Hiller, Á.; Pegg, E.; Saville, R.; Weng, S.; Luzzio, M.; Uster, P.; Amantea, M.; Working, P. K. Encapsulation of the topoisomerase I inhibitor GL14721]C in pegylated (STEALTH) liposomes: Pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin. Cancer Res. 1998, 4, 3077-3082.
12. Emerson, D. L.; Bendele, R.; Brown, E.; Chiang, S.; Desjardins, J. P.; Dihel, L. C.; Gill, S. C.; Hamilton, M.; LeRay, J. D.; Moon-McDermott, L.; Moynihan, K.; Richardson, F. C.; Tomkinson, B.; Luzzio, M. J.; Baccanari, D. Antitumor efficacy, pharmacokinetics, and biodistribution of NX-211: A low-clearance liposomal formulation of lurtotecan. Clin. Cancer Res. 2000, 6, 2903-2912.
13. Tardi, P.; Choice, E.; Masin, D.; Redelmeier, T.; Bally, M.; Madden, T. D. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res. 2000, 60, 3389-3393.
14. Messerer, C. L.; Ramsay, E. C.; Waterhouse, D.; Ng, R.; Simms, E.-M.; Harasym, N.; Tardi, P.; Mayer, L. D.; Bally, M. B. Liposomal irinotecan: Formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin. Cancer Res. 2004, 10, 6638-6649.
15. Pal, A.; Khan, S.; Wang, Y.-F.; Kamath, N.; Sarkar, A. K.; Ahmad, A.; Sheikh, S.; Ali, S.; Carbonaro, D.; Zhang, A.; Ahmad, I. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res. 2005, 25, 331-342.
16. Zamboni, W. C.; Jung, L. L.; Strychor, S.; Joseph, E.; Fetterman, S. A.; Burke, T. G.; Curran, D. P.; Egorin, M. J.; Eiseman, J. L. Disposition of non-liposomal DB-67 and bilayer liposomal DB-67 in non-tumor-bearing CB-17 SCID mice. Unpublished results.
17. Liu, X.; Zhang, J.; Song, L.; Lynn, B. C.; Burke, T. G. Degradation of camptothecin-20(S)-glycinate ester prodrug under physiological conditions. J. Pharm. Biomed. Anal. 2004, 35, 1113-1125.
18. Greenwald, R. B.; Pendri, A.; Conover, C. D.; Lee, C.; Choe, Y. H.; Gilbert, C.; Martinez, A.; Xia, J.; Wu, D.; Hsue, M.-M. Camptothecin-20-PEG ester transport forms: The effect of spacer groups on antitumor activity. Bioorg. Med. Chem. 1998, 6, 551-562.
19. Zhao, H.; Lee, C.; Sai, P.; Choe, Y. H.; Boro, M.; Pendri, A.; Guan, S.; Greenwald, R. B. 20-O-Acylcamptothecin derivatives: Evidence for lactone stabilization. J. Org. Chem. 2000, 65, 4601-4606.
20. 15N Nuclear Magnetic Resonance Spectroscopy; Wiley-Interscience: New York, 1979.
21. Cao, Z.; Harris, N.; Kozielski, A.; Vardeman, D.; Stehlin, J. S.; Giovanella, B. AIkyl esters of camptothecin and 9-nitrocamptothecin: Synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. J. Med. Chem. 1998, 41, 31-37.
22. de Groot, F. M.; Busscher, G. F.; Aben, R. W.; Scheeren, H. W. Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin. Bioorg. Med. Chem. Lett. 2002, 12, 2371-2376.
23. Lerchen, H. G.; Baumgarten, J.; von dem Bruch, K.; Lehmann, T. E.; Sperzel, M.; Kempka, G.; Fiebig, H. H. Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents. J. Med. Chem. 2001, 44, 4186-4195.
24. Vishnuvajjala, R.; Garzon-Aburbey, A. Preparation of water-soluble derivatives of camptothecin and their use as prodrugs in cancer therapy. U.S. Patent No. 4943579, 1990.
25. Yang, L. X.; Pan, X.; Wang, H. J. Novel camptothecin derivatives, part 1: Oxyalkanoic acid esters of camptothecin and their in vitro and in vivo antitumor activity. Bioorg. Med. Chem. Lett. 2002, 12, 1241-1244.
26. Warnecke, A.; Kratz, F. Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: Synthesis and antitumor efficacy. Bioconjugate Chem. 2003, 14, 377-387.
27. Wadkins, R. M.; Potter, P. M.; Vladu, B.; Marty, J.; Mangold, G.; Weitman, S.; Manikumar, G.; Wani, M. C.; Wall, M. E.; Von Hoff, D. D. Water soluble 20(S)-glycinate esters of 10,11-methylenedioxy-camptothecins are highly active against human breast cancer xenografts. Cancer Res. 1999, 59, 3424-3428.
28. Taft, R. W. Steric Effects in Organic Chemistry: Wiley: New York, 1956; p Chapter 13.
29. Anderson, B. D.; Conradi, R. A.; Knuth, K. E. Strategies in the design of solution stable, water soluble prodrugs. I. A physical organic approach to pro-moiety selection for 2I-esters of corticosteroids. J. Pharm. Sci. 1985, 74, 365-374.
30. Kirby, A. J.; Komarov, L. V.; Feeder, N. Synthesis, structure and reactions of the most twisted amide. J. Chem. Soc. Perkin Trans. 1 2001, 2, 522-529.
31. Cordes, E. H.; Bull, H. G. Mechanism and catalysis for hydrolysis of acetals, ketals, and ortho esters. Chem. Rev. 1974, 74, 581-603.
32. McClelland, R. A. Rate-limiting deprotonation in tetrahedral intermediate breakdown. J. Am. Chem. Soc. 1984, 106, 7579-7583.
33. Santry, L. J.; McClelland, R. A. Orientation effects on the rate and equilibrium constants for formation and decomposition of tetrahedral intermediates. J. Am. Chem. Soc. 1983. 105, 6138-6141.
34. Deslongchamps, P. Stereoelectronic control in the cleavage of tetrahedral intermediates in the hydrolysis of esters and amides. Tetrahedron 1975, 31, 2643-2690.
35. Deslongchamps, P. The importance of conformation of the tetrahedral intermediate in the hydrolysis of esters and amides. Pure Appl. Chem. 1975, 43, 351-378.
36. Deslongchamps, P. Stereoelectronic control in hydrolytic reactions. Heterocycles 1977, 7, 1271-1317.
37. Adamovics, J. A.; Hutchinson, C. R. Prodrug analogues of the antitumor alkaloid camptothecin. J. Med. Chem. 1979, 22, 310-314.